Cargando…

Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response

BACKGROUND: Neutralizing antibodies are considered a key correlate of protection by current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic SARS-CoV-2 antibodies, including convalescent plasma therapy, remains to be fully elucidated. METHODS: We conducted a proof-of-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marconato, Maddalena, Abela, Irene A., Hauser, Anthony, Schwarzmüller, Magdalena, Katzensteiner, Rheliana, Braun, Dominique L., Epp, Selina, Audigé, Annette, Weber, Jacqueline, Rusert, Peter, Schindler, Eméry, Pasin, Chloé, West, Emily, Böni, Jürg, Kufner, Verena, Huber, Michael, Zaheri, Maryam, Schmutz, Stefan, Frey, Beat M., Kouyos, Roger D., Günthard, Huldrych F., Manz, Markus G., Trkola, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197521/ https://www.ncbi.nlm.nih.gov/pubmed/35482408 http://dx.doi.org/10.1172/JCI158190

Ejemplares similares

Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity
por: Brown, Jennifer A, et al.
Publicado: (2023)

Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
por: Abela, Irene A., et al.
Publicado: (2021)

Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies
por: Abela, Irene A., et al.
Publicado: (2012)

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters
por: Brandenberg, Oliver F., et al.
Publicado: (2017)

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
por: Huang, Alice, et al.
Publicado: (2022)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain’s exceptional capacity for sequence variation
por: Brandenberg, Oliver F, et al.
Publicado: (2014)

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
por: Cicin-Sain, Caroline, et al.
Publicado: (2021)

Assessing immunogenicity barriers of the HIV-1 envelope trimer
por: Maliqi, Liridona, et al.
Publicado: (2023)

Reply to correspondence ‘Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a “stochastic” process’ by Gonzalez et al., Retrovirology 2017
por: Oberle, Corinna S., et al.
Publicado: (2017)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity
por: Kadelka, Claus, et al.
Publicado: (2018)

Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases
por: Kufner, Verena, et al.
Publicado: (2019)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells
por: Liechti, Thomas, et al.
Publicado: (2019)

SARS-CoV-2 variants reveal features critical for replication in primary human cells
por: Pohl, Marie O., et al.
Publicado: (2021)

HIV-1 replication activates CD4(+) T cells with specificities for persistent herpes viruses
por: Haas, Anna, et al.
Publicado: (2010)

Editorial Commentary: The Irreversibility of HIV Drug Resistance
por: Kouyos, Roger D., et al.
Publicado: (2015)

OMIP‐047: High‐Dimensional phenotypic characterization of B cells
por: Liechti, Thomas, et al.
Publicado: (2018)

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
por: Griessbach, Alexandra, et al.
Publicado: (2023)

High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children
por: Huber, Michael, et al.
Publicado: (2021)

Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs
por: Audigé, Annette, et al.
Publicado: (2021)

Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
por: Griessbach, Alexandra, et al.
Publicado: (2023)

Does respiratory co-infection facilitate dispersal of SARS-CoV-2? investigation of a super-spreading event in an open-space office
por: Weissberg, Dana, et al.
Publicado: (2020)

Correction to: Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples
por: Lewandowska, Dagmara W., et al.
Publicado: (2017)

Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples
por: Lewandowska, Dagmara W., et al.
Publicado: (2017)

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2022)

Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs
por: Oberle, Corinna S., et al.
Publicado: (2016)

Inferring Epidemic Contact Structure from Phylogenetic Trees
por: Leventhal, Gabriel E., et al.
Publicado: (2012)

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent
por: Reh, Lucia, et al.
Publicado: (2015)

P09-02. Selection pressure of neutralizing antibodies and viral escape continues in late stages of the disease
por: Rusert, P, et al.
Publicado: (2009)

Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup
por: Bachmann, Nadine, et al.
Publicado: (2017)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Phylodynamics on local sexual contact networks
por: Rasmussen, David A., et al.
Publicado: (2017)

Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics
por: Kühnert, Denise, et al.
Publicado: (2018)

Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds
por: Yang, Wan-Lin, et al.
Publicado: (2015)

Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting
por: Kouyos, Roger D., et al.
Publicado: (2011)

Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1–infected Eritrean Immigrant
por: Bansal, Vineeta, et al.
Publicado: (2011)

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018
por: Jaha, Bashkim, et al.
Publicado: (2023)

Functional Antibodies in COVID-19 Convalescent Plasma
por: Herman, Jonathan D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qi7gubdb6j2ptqlgnvs628n3ji